Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01110-18. doi: 10.1128/AAC.01110-18. Print 2019 Jan.

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Author information

1
Istanbul Education and Research Hospital, Istanbul, Turkey.
2
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
3
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
4
Case Western Reserve University Veterans Affairs Center of Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
5
The University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia d.paterson1@uq.edu.au.

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

KEYWORDS:

Acinetobacter ; cefiderocol

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center